Hints and tips:
Related Special Reports
...In a speech at Monday’s gathering, Gates is expected to underscore the case for making nutrition and gut microbes — known as the microbiome — a leading area of international research....
...Peter Lacy, Accenture’s former head of sustainability and a member of its global management committee, claimed that he was “belittled” and “shamed” by Julie Sweet, Accenture’s chair and chief executive,...
...While acknowledging that AstraZeneca has “a global reach, is in a high-paying sector, with a particularly well-regarded CEO at the helm,” ISS said that it remained concern by “the scale of the increase”....
...“There is a compensation issue at AstraZeneca,” Jain, a top-20 shareholder, told the Financial Times....
...In recommending that investors oppose the plans, ISS said it acknowledged that AstraZeneca, the UK’s second-largest public company by market value, has “a global reach, is in a high-paying sector, with a...
...AstraZeneca is withdrawing its Covid-19 jab, saying there is a “surplus of available updated vaccines” and that its product is no longer being manufactured or supplied....
...The company is contesting a legal case from Jamie Scott, who claims he developed a severe blood clot because he took the vaccine....
...“It’s traditionally been a story that’s popular with UK fund managers. It’s easy to explain, traditionally pays a dividend, and has lots of analyst coverage,” Dixon said....
...GSK raised its guidance for 2024 on the back of a 10 per cent increase in sales in the first quarter of the year....
...“Getting that to a close is a very important milestone,” Philip’s chief executive Roy Jakobs told the Financial Times....
...The results signal a continued strong start to the year for GSK, whose shares are up by more than 15 per cent since January — well ahead of the FTSE 100, including a rise of almost 2 per cent in morning...
...The suit filed in Delaware district court on Thursday is the latest in a string of actions taken against Pfizer and BioNTech over their Comirnaty vaccine....
...It recently sold a large site in California to contract manufacturer Lonza for $1.2bn....
...drug breaks down into a carcinogen....
...than a decade....
...or offer solutions for patients at a later stage.”...
...As Emblaveo is a combination of two existing antibiotic treatments, aztreonam and avibactam, it would not qualify as a “priority” drug eligible for a voucher....
...Smith & Nephew survived a major shareholder revolt over a $2.6mn potential pay rise for its chief executive, in the latest controversy on executive remuneration by UK-listed companies competing with high-paying...
...“The number of patients seeking care is so significant that we don’t see a lot of switching.”...
...“This industry is a global industry and a lot of the talent is based in the US.”...
...“The whole system has a just-in-time principle and any rupture in that causes a downstream shortage,” says Rob Moss, a hospital pharmacy consultant in Utrecht, the Netherlands....
...These price concessions increased from 20 instances per month before 2016 to a peak of 199 per month in late 2022....
...“This is not a problem just for the heroin users. This is a problem for a wider population of people who use drugs, who might not think that they’re at risk of xylazine harm,” she added....
...Properly funded public health interventions are a good example, says Dave Buck, a senior fellow in public health and inequalities at the King’s Fund, a British health think-tank....
International Edition